EUVIMEDEUVIMED entdecken
Crossref

Effects of Burosumab Treatment on Mineral Metabolism in Children and Adolescents With X-linked Hypophosphatemia

Annika Ewert, Mirko Rehberg iD, Karl Peter Schlingmann, Olaf Hiort iD, Ulrike John-Kroegel, Oliver Metzing, Elke Wühl, Franz Schaefer, Markus J Kemper, Ute Derichs, Annette Richter-Unruh, Ludwig Patzer und 14 weitere

The Journal of Clinical Endocrinology & Metabolism · 2023

DOI: 10.1210/clinem/dgad223 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2023. Verfasst von Annika Ewert und 25 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Kidney, Liver and Metabolic Diseases, Hannover Medical School, Hannover 30625, Germany. Hauptthemen laut MEDLINE: Familial Hypophosphatemic Rickets, Hypophosphatemia. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 46 Literaturangaben. Gefördert von: Kyowa Kirin, Germany.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

Burosumab has been approved for the treatment of children and adults with X-linked hypophosphatemia (XLH). Real-world data and evidence for its efficacy in adolescents are lacking.

Objective

To assess the effects of 12 months of burosumab treatment on mineral metabolism in children (aged <12 years) and adolescents (aged 12-18 years) with XLH.

Design

Prospective national registry.

Setting

Hospital clinics. Patients A total of 93 patients with XLH (65 children, 28 adolescents). Main Outcome Measures Z scores for serum phosphate, alkaline phosphatase (ALP), and renal tubular reabsorption of phosphate per glomerular filtration rate (TmP/GFR) at 12 months.

Results

At baseline, patients showed hypophosphatemia (−4.4 SD), reduced TmP/GFR (−6.5 SD), and elevated ALP (2.7 SD, each P < .001 vs healthy children) irrespective of age, suggesting active rickets despite prior therapy with oral phosphate and active vitamin D in 88% of patients. Burosumab treatment resulted in comparable increases in serum phosphate and TmP/GFR in children and adolescents with XLH and a steady decline in serum ALP (each P < .001 vs baseline). At 12 months, serum phosphate, TmP/GFR, and ALP levels were within the age-related normal range in approximately 42%, 27%, and 80% of patients in both groups, respectively, with a lower, weight-based final burosumab dose in adolescents compared with children (0.72 vs 1.06 mg/kg, P < .01).

Conclusions

In this real-world setting, 12 months of burosumab treatment was equally effective in normalizing serum ALP in adolescents and children, despite persistent mild hypophosphatemia in one-half of patients, suggesting that complete normalization of serum phosphate is not mandatory for substantial improvement of rickets in these patients. Adolescents appear to require lower weight-based burosumab dosage than children.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Familial Hypophosphatemic RicketsHypophosphatemiaAdultHumansChildAdolescentAntibodies, MonoclonalProspective StudiesPhosphatesFibroblast Growth FactorsMineralsAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

TmP/GFRX-linked hypophosphatemiaadolescentsalkaline phosphataseburosumabchildrenhyperparathyroidismphosphaterickets

Substanzen

Antibodies, MonoclonalPhosphatesFibroblast Growth FactorsMineralsburosumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Pediatric Kidney, Liver and Metabolic Diseases, Hannover Medical School, Hannover 30625, Germany.
  • Department of Pediatrics, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne 50937, Germany.
  • Department of General Pediatrics, Pediatric Nephrology, University Children's Hospital, Münster 48149, Germany.
  • Division of Pediatric Endocrinology and Diabetes, Department of Pediatrics and Adolescent Medicine, University of Lübeck, Lübeck 23562, Germany.
  • University Children's Hospital, Jena 07743, Germany.
  • Division of Pediatric Nephrology, Center for Pediatric and Adolescent Medicine, University Hospital Heidelberg, Heidelberg 69120, Germany.

ORCID-Profile: Mirko Rehberg, Olaf Hiort, Maren Leifheit-Nestler, Dieter Haffner

Förderung

  • Kyowa Kirin, Germany

Zitieren

APA

Ewert, A., Rehberg, M., Schlingmann, K. P., Hiort, O., John-Kroegel, U., Metzing, O., Wühl, E., Schaefer, F., Kemper, M. J., Derichs, U., Richter-Unruh, A., Patzer, L., Albers, N., Dunstheimer, D., Haberland, H., Heger, S., Schröder, C., Jorch, N., Schmid, E., …, & Haffner, D. (2023). Effects of Burosumab Treatment on Mineral Metabolism in Children and Adolescents With X-linked Hypophosphatemia. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgad223

Vancouver

Ewert A, Rehberg M, Schlingmann KP, Hiort O, John-Kroegel U, Metzing O, et al. Effects of Burosumab Treatment on Mineral Metabolism in Children and Adolescents With X-linked Hypophosphatemia. The Journal of Clinical Endocrinology & Metabolism. 2023. doi:10.1210/clinem/dgad223

BibTeX
@article{Ewert2023,
  author = {Ewert, Annika and Rehberg, Mirko and Schlingmann, Karl Peter and Hiort, Olaf and John-Kroegel, Ulrike and Metzing, Oliver and Wühl, Elke and Schaefer, Franz and Kemper, Markus J and Derichs, Ute and Richter-Unruh, Annette and Patzer, Ludwig and Albers, Norbert and Dunstheimer, Desiree and Haberland, Holger and Heger, Sabine and Schröder, Carmen and Jorch, Norbert and Schmid, Elmar and Staude, Hagen and Weitz, Marcus and Freiberg, Clemens and Leifheit-Nestler, Maren and Zivicnjak, Miroslav and Schnabel, Dirk and Haffner, Dieter},
  title = {Effects of Burosumab Treatment on Mineral Metabolism in Children and Adolescents With X-linked Hypophosphatemia},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2023},
  doi = {10.1210/clinem/dgad223}
}
Kostenlos starten →